Skip to main content

Advertisement

Fig. 4 | Breast Cancer Research

Fig. 4

From: The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

Fig. 4

Kaplan-Meier estimates of disease-free survival in patients with luminal (Lum) A (a), luminal B (b), basal-like (c), and human epidermal growth factor receptor 2-enriched (HER2-E) (d) breast cancer in the systemically untreated arm (–CT) and in the cyclophosphamide/cyclophosphamide, methotrexate and fluorouracil arm (+CT)

Back to article page